-

ForgeRock, Inc. (FORG) Shareholder Alert: Robbins LLP Informs Stockholders it is Investigating the Acquisition of ForgeRock, Inc. by Thoma Bravo

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of ForgeRock, Inc. (NYSE: FORG) by Thoma Bravo. Under the terms of the agreement, ForgeRock stockholders will receive $23.25 in cash for each share of ForgeRock common stock owned.

If you own shares of ForgeRock, Inc., click here.

Is the Proposed Acquisition Best for ForgeRock, Inc. (FORG) and Its Shareholders?

In October 2022, ForgeRock announced a deal to be acquired by private-equity firm Thoma Bravo. According to the Proxy Statement, ForgeRock's board approved a merger agreement with Thoma Bravo for $23.25 per share in cash. The deal is valued at approximately $2.3 billion and is expected to close the first half of 2023. Robbins LLP is concerned that ForgeRock's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Next Steps: If you own shares of ForgeRock, Inc. (FORG) you have legal options. Contact us to learn more about your legal rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against ForgeRock, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:FORG

Release Summary
Robbins LLP is Investigating the Acquisition of ForgeRock, Inc. by Thoma Bravo
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges Investors Who Lost Money Investing in Upstart Holdings, Inc. to Contact the Firm for Information About Leading the Class Action Against UPST

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Upstart Holdings, Inc. (NASDAQ: UPST) securities between May 14, 2025 and November 4, 2025. Upstart, together with its subsidiaries, operates a cloud-based artificial intelligence (“AI”) lending platform in the U.S.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.What is the class period?...

Robbins LLP Urges Investors Who Lost Money Investing in Stellantis N.V. to Contact the Firm for Information About Leading the Class Action Against STLA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stellantis N.V. (NYSE: STLA) securities between February 26, 2025 and February 5, 2026. Stellantis is a global automobile designer, engineer, manufacturer, and distributor.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.What is the class period? February 26, 2025 – February 5, 2026What a...

Robbins LLP Urges Investors Who Lost Money Investing in Medpace Holdings Inc. to Contact the Firm for Information About Leading the Class Action Against MEDP

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Medpace Holdings Inc. (NASDAQ: MEDP) securities between April 22, 2025 and February 9, 2026. Medpace is a clinical contract research organization (CRO) focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.For more information, submit a form, email...
Back to Newsroom